Efficacy and Safety of Drug-Eluting Stents in Chronic Total Coronary Occlusion Recanalization A Systematic Review and Meta-Analysis

被引:102
|
作者
Colmenarez, Humberto J.
Escaned, Javier [1 ]
Fernandez, Cristina [2 ]
Lobo, Liliana
Cano, Sara [2 ]
del Angel, Juan G.
Alfonso, Fernando
Jimenez, Pilar
Banuelos, Camino
Gonzalo, Nieves
Garcia, Eulogio
Hernandez, Rosana
Macaya, Carlos
机构
[1] Hosp Clin San Carlos, Unidad Cardiol Intervencionista, Cardiovasc Inst, Madrid 28040, Spain
[2] Hosp Clin San Carlos, Prevent Med Unit, Madrid 28040, Spain
关键词
chronic total occlusion; drug-eluting stent; meta-analysis; stent; BARE-METAL; FOLLOW-UP; ANGIOGRAPHIC OUTCOMES; BALLOON ANGIOPLASTY; CLINICAL-OUTCOMES; IMPLANTATION; SIROLIMUS; ARTERIES; INTERVENTION;
D O I
10.1016/j.jacc.2009.12.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The aim of this study was to compare the efficacy and safety of drug-eluting stent (DES) and bare-metal stent (BMS) use in chronic total occlusion (CTO) recanalization. Background The long-term effectiveness and safety of DES use in CTO recanalization are unclear, and performance of randomized clinical trials in the field is complex. Methods Major electronic information sources were explored for articles comparing outcomes with DES and BMS use among patients with CTO. Assessed clinical outcomes were death, myocardial infarction, target vessel revascularization, major adverse cardiac events, and stent thrombosis; angiographic outcomes were stent restenosis and stent reocclusion. Results Fourteen comparative studies were identified (a total of 4,394 patients). When compared with BMS, DES significantly reduced risk of major adverse cardiac events (relative risk [RR]: 0.45, 95% confidence interval [CI]: 0.34 to 0.60, p < 0.001) and TVR (RR: 0.40, 95% CI: 0.28 to 0.58, p < 0.001) without increasing death (RR: 0.87, 95% CI: 0.66 to 1.16, p = 0.88) or myocardial infarction (RR: 0.89, 95% CI: 0.54 to 1.46, p = 0.80). This benefit was sustained at >= 3 years of follow-up. Lower RRs for restenosis (RR: 0.25, 95% CI: 0.16 to 0.41, p < 0.001) and stent reocclusion (RR: 0.30, 95% CI: 0.18 to 0.49, p < 0.001) were also observed in the DES group. A strong trend toward a higher rate of stent thrombosis was documented in DES-treated patients (RR: 2.79, 95% CI: 0.98 to 7.97, p = 0.06). Conclusions DES use in CTO recanalization is associated with significantly fewer major adverse cardiac events and fewer occurrences of target vessel revascularization, restenosis, and stent reocclusion than with BMS. Although a statistical trend toward a higher risk of stent thrombosis was observed, the use of DES in this context seems to be safe, with an overall benefit sustained in the long term. (J Am Coll Cardiol 2010; 55: 1854-66) (C) 2010 by the American College of Cardiology Foundation
引用
收藏
页码:1854 / 1866
页数:13
相关论文
共 50 条
  • [21] The Efficacy and Safety of Transradial and Transfemoral Approach in Treatment of Coronary Chronic Total Occlusion: A Systematic Review and Meta-Analysis
    Soud, Mohamad
    SayedAhmad, Ziad
    Kajy, Marvin
    Al-Khadra, Yasser
    Darmoch, Fahed
    Pacha, Homam Moussa
    Shah, Zeel
    Tayal, Rajiv
    Kaki, Amir
    Basir, Babar
    Alraies, M. Chadi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (13) : B217 - B217
  • [22] Systematic Review of Infrapopliteal Drug-Eluting Stents: A Meta-Analysis of Randomized Controlled Trials
    Katsanos, Konstantinos
    Spiliopoulos, Stavros
    Diamantopoulos, Athanasios
    Karnabatidis, Dimitris
    Sabharwal, Tarun
    Siablis, Dimitris
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2013, 36 (03) : 645 - 658
  • [23] Systematic Review of Infrapopliteal Drug-Eluting Stents: A Meta-Analysis of Randomized Controlled Trials
    Konstantinos Katsanos
    Stavros Spiliopoulos
    Athanasios Diamantopoulos
    Dimitris Karnabatidis
    Tarun Sabharwal
    Dimitris Siablis
    CardioVascular and Interventional Radiology, 2013, 36 : 645 - 658
  • [24] Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials
    Brar, Somjot S.
    Gray, William A.
    Dangas, George
    Leon, Martin B.
    Aharonian, Vicken J.
    Brar, Simerjeet K.
    Moses, Jeffrey W.
    EUROINTERVENTION, 2009, 5 (04) : 475 - 484
  • [25] Use of Drug-Eluting Stents in Acute Myocardial Infarction A Systematic Review and Meta-Analysis
    Brar, Somjot S.
    Leon, Martin B.
    Stone, Gregg W.
    Mehran, Roxana
    Moses, Jeffrey W.
    Brar, Simerjeet K.
    Dangas, George
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (18) : 1677 - 1689
  • [26] Drug-Eluting Stents Versus Bare-Metal Stents in Large Coronary Artery Revascularization: Systematic Review and Meta-Analysis
    Changal, Khalid Hamid
    Mir, Tanveer
    Khan, Shayan
    Nazir, Salik
    Elzanatey, Ahmed
    Meenakshisundaram, Chandramohan
    Mubbasher, Syed
    Sheikh, Mujeeb A.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2021, 23 : 42 - 49
  • [27] Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta-analysis
    Yin, Juntao
    Li, Yang
    Chen, Yangyang
    Wang, Chaoyang
    Song, Xiaoyong
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [28] Benefits of drug-eluting stents: a meta-analysis
    Nature Clinical Practice Cardiovascular Medicine, 2004, 1 (1): : 4 - 4
  • [29] Safety and efficacy of drug-eluting stents in acute coronary syndromes
    Ivanes, Fabrice
    Bauchart, Jean-Jacques
    Van Belle, Eric
    SANG THROMBOSE VAISSEAUX, 2010, 22 (06): : 284 - 288
  • [30] Effectiveness and Safety of Drug-Eluting Stents in Vein Grafts: A Meta-Analysis
    Joyal, Dominique
    Filion, Kristian
    Eisenberg, Mark J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (6A): : 153D - 153D